Manufacturing

AstraZeneca opened a $300 million cell therapy facility in May of 2025 in Rockville, Md. Developed by Alexandria Real Estate Equites, the 84,264-rsf building features specialized environments for the production of chimeric antigen receptor therapies (CAR-T) and T-cell receptor therapies (TCR-T). Next-generation biomanufacturing suites will leverage advanced process controls to create life-saving personalized medicine treatments, spanning every step from culturing and formulation to testing.

Harwell began construction in early 2025 on Tech Foundry West in the United Kingdom. This dynamic nexus is rising on the Harwell Science and Innovation Campus in Oxfordshire and will offer 70,000 sf of leasable laboratory, advanced manufacturing, and office space. Designed by Scott Brownrigg, the development integrates individual units within a flexible layout to ensure future adaptability to varying multi-tenant arrangements.

Siemens Mobility will begin construction in early 2025 on a £100 million innovation center for rail infrastructure in Chippenham, U.K. Designed by Arup and AHR, the digitally enabled complex will provide world-class R&D labs for the creation of novel transit solutions. Integrated research, testing, and factory environments will accelerate the production of the next generation of signaling and control systems for the United Kingdom.

The University of Sheffield's Advanced Manufacturing Research Centre finished construction in November of 2024 on an open-access innovation facility for aerospace R&D in the United Kingdom. Expanding the capabilities of the adjacent Factory 2050, the 29,700-sf structure will initially house the Composites at Speed and Scale (COMPASS) initiative. An expansive factory environment will enable academic, government, and industry partners to work side-by-side, complemented by individual workshops and ancillary spaces.

The Canadian Centre for Advanced Material Manufacturing (CCAM) opened in Mississauga in fall of 2024. The transformation of the existing building was designed by the Canada FIRST joint venture, a collaboration between HOK, Architecture49, and WSP. The ambitious project represents the first milestone in the Laboratories Canada program, a strategic initiative by the federal government aimed at modernizing and enhancing science facilities across the nation.

The University of Maine broke ground in October of 2024 on the $81 million Green Engineering and Materials (GEM) building in Orono. Designed by SMRT Architects & Engineers and Grimshaw Architects, the 50,000-sf project will house the Factory of the Future, a test bed for large-format additive manufacturing. Academic spaces for the Maine College of Engineering and Computing will be collocated with active research environments, offering unique opportunities for immersive learning.

Clemson University is constructing the Advanced Materials Innovation Complex in Clemson, S.C. The 143,000-sf facility will feature collaborative research suites where teams of investigators can discover new technologies for advanced manufacturing, energy, and health. HOK's innovative design for the center strengthens interdisciplinary synergies by collocating the Department of Materials Science and Engineering with select faculty from the Department of Chemistry and the Department of Chemical and Biomedical Engineering.

The number of makerspaces has increased 200% nationally in the last decade, with no sign of slowing down. This bodes well for the future of the labor force. But given the type of technology and materials used in these spaces, they also present a multitude of code, infrastructure, and safety challenges. Assess the risks posed by the various makerspace activities, and learn the regulations that apply to everything from welding and wood processing to painting and 3D printing. 

BeiGene opened an $800 million center for biologics manufacturing and research in July of 2024 in Hopewell, N.J. Sited on 42 acres at the Princeton West Innovation Campus, the development provides 400,000 sf of dedicated space for commercial-stage production of cancer therapies. A 100,000-sf lab building accommodates clinical R&D suites and collaborative office settings. As BeiGene's U.S. headquarters and flagship manufacturing facility, the highly flexible complex integrates universal design principles to create an adaptable, human-centric environment.

BXP recently completed a 113,000-rsf innovation hub in Waltham, Mass. Designed by TRIA, 103 CityPoint aims to reshape corporate culture for science and technology tenants, energizing its workforce and accelerating growth. The flexible flour-story structure provides 80 percent laboratory and office space, with 20 percent accommodating a double-height cGMP manufacturing area spanning approximately 25,000 sf.

WACKER opened the mRNA Competence Center in June of 2024 in Halle an der Saale, Germany. Representing an investment of over €100 million, the next-generation facility enables the large-scale production of active ingredients based on messenger ribonucleic acid (mRNA). The building spans a total floor area of 79,653 sf and accommodates four new lines supported by advanced infrastructure, including 17,222 sf of glass-enclosed cleanroom space for bioprocessing under controlled conditions. 

Cincinnati Children’s Hospital Medical Center began construction in June of 2024 on the Applied Gene and Cell Therapy Center in Sharonville, Ohio. The $60 million project will transform an existing structure into a catalyst for innovative clinical trials. Designed by BHDP Architecture, the 111,000-sf facility will advance the development, testing, and manufacture of new medicines and biological therapies.

Sanofi opened a 20,000-sf biomanufacturing center in May of 2024 in Toronto. Producing adult and pediatric vaccines for pertussis, diphtheria, and tetanus, the project significantly increases capacity to meet growing demand in Canada and around the world. The next-generation facility features advanced bioprocessing suites supported by highly efficient infrastructure. Commissioning is currently under way, with full operations slated to commence in mid-2025.

AstraZeneca is planning to construct a US$1.5 billion facility in Singapore for the manufacture of antibody drug conjugates (ADCs). Enabling the creation of precision cancer therapies, the project will integrate every stage of the ADC production process at commercial scale. The sustainably designed building is slated to achieve net-zero operational carbon and will leverage advanced infrastructure to achieve optimal energy performance. Completion is expected in 2029. A site for the greenfield development has yet to be determined. 

Siemens Healthineers—a spinoff of Siemens that focuses exclusively on healthcare equipment, solutions, and services—has begun construction on a £250 million ($314 million) facility in the United Kingdom to research and manufacture a breakthrough sustainable design for MRI superconducting magnets that reduces the need for helium from 1,500 liters (more than 396 gallons) to a single liter (just over a quart).